The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

AstraZeneca hails progress on chronic kidney disease with US approval

Mon, 3rd May 2021 07:58

(Alliance News) - Farxiga has been approved by the US Food & Drug Administration for treatment of chronic kidney disease, AstraZeneca PLC said late Friday.

The approval of Farxiga, whose generic name is dapagliflozin, "is the most significant advancement in the treatment of chronic kidney disease in more than 20 years," the Cambridge, England-based pharmaceutical firm said.

The US approval was based on positive results from the DAPA-CKD Phase III trial, AstraZeneca said, and follows the grant of a priority review by the FDA earlier this year.

The approval of Farxiga was for the reduction in the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease at risk of progression. Some 37 million people in the US have chronic kidney disease, Astra noted.

"Today's approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years," said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca. "We've shown impressive efficacy for Farxiga in type-2 diabetes, heart failure with reduced ejection fraction and, most recently, chronic kidney disease, and we are thrilled to be able to bring this medicine to millions of patients in the US."

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

AstraZeneca's Koselugo gets EU regulatory approval to treat children

AstraZeneca's Koselugo gets EU regulatory approval to treat children

Today 09:01

AstraZeneca given EU approval for use of Koselugo in children

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.

Today 08:25

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

18 Jun 21 17:04

UPDATE: Both EU and Astra pleased with court outcome on vaccines

UPDATE: Both EU and Astra pleased with court outcome on vaccines

18 Jun 21 14:03

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.